Patents by Inventor QUN DU

QUN DU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250121104
    Abstract: Compounds, e.g., radioimmunoconjugates, including a chelating moiety or a metal complex thereof, a linker, and an antibody or antigen-binding fragment thereof targeting both EGFR and cMET. Pharmaceutical compositions of such compounds and methods of treatment for conditions, e.g., cancer, using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: December 20, 2022
    Publication date: April 17, 2025
    Inventors: Sadaf AGHEVLIAN, Natalie GRINSHTEIN, Ian R. DUFFY, Thomas I. KOSTELINK, Andrew Grier BUCHANAN, Yariv MAZOR, Srinath KASTURIRANGAN, Qun DU, Chunning YANG, Frank Irvine COMER
  • Publication number: 20250115678
    Abstract: The disclosure generally relates to binding proteins that comprise antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site. The disclosure also relates to pharmaceutical compositions comprising such binding proteins, nucleic acid molecules encoding such binding proteins, and vectors comprising such nucleic acid molecules. The disclosure further relates to methods of treating a disorder or condition using such binding proteins and pharmaceutical compositions, binding proteins and pharmaceutical compositions for use in the treatment of a disorder or condition, and the use of such binding proteins and pharmaceutical compositions for the manufacture of a medicament for treating a disorder or condition.
    Type: Application
    Filed: October 9, 2024
    Publication date: April 10, 2025
    Inventors: Mark COBBOLD, Corinne CAYATTE, Thomas CIUCCI, Yariv MAZOR, Saso CEMERSKI, Simon DOVEDI, Christopher LLOYD, Jonathan SEAMAN, Dominique LISIERO, Hanzhi ZHANG, Qun DU, Tilbe CREIGH-PULATMEN, Gilad KAPLAN, Cristina BERGAMASCHI, Xiuling LI, Ying FU, Amber LEE, Alan SANDERCOCK, Vijay CHENNUPATI, Sterling R. PAYNE, Abigail Bowlsbey LARA, Laure CASTAN, Isabelle SERMADIRAS, Owen VICKERY, Suzanne SITNIKOVA, Even WALSENG
  • Publication number: 20240360226
    Abstract: The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The antibody molecules and conjugates find application in the treatment of cancer, for example.
    Type: Application
    Filed: June 25, 2024
    Publication date: October 31, 2024
    Inventors: Frank Irvine COMER, Yariv MAZOR, Srinath KASTURIRANGAN, Qun DU, Chunning YANG, Andrew Grier BUCHANAN
  • Patent number: 12065496
    Abstract: The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The antibody molecules and conjugates find application in the treatment of cancer, for example.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: August 20, 2024
    Assignee: AstraZeneca AB
    Inventors: Frank Irvine Comer, Yariv Mazor, Srinath Kasturirangan, Qun Du, Chunning Yang, Andrew Grier Buchanan
  • Publication number: 20240182548
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and selecting the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2 infection in subject.
    Type: Application
    Filed: November 30, 2023
    Publication date: June 6, 2024
    Inventors: Mark ESSER, James STEINHARDT, Patrick MCTAMNEY, II, Yueh-Ming LOO, Reena M. VARKEY, Qun DU, Saravanan RAJAN
  • Publication number: 20240092875
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of using such antibodies and antigen-binding fragments thereof for the prevention and treatment of Coronavirus Disease 2019 (COVID-19) in a subject.
    Type: Application
    Filed: August 9, 2023
    Publication date: March 21, 2024
    Inventors: Robert GASSER, Mark ESSER, Patrick MCTAMNEY, II, Yueh-Ming LOO, Reena M. VARKEY, Qun DU, James STEINHARDT, Saravanan RAJAN
  • Publication number: 20230279078
    Abstract: The present disclosure provides SARS-CoV-2 spike proteins and trimers containing such spike proteins. The present disclosure also provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2. The proteins, trimers, and antibodies can be used, for example, to detect anti-SARS-CoV-2 antibodies in sample obtained from a subject.
    Type: Application
    Filed: July 19, 2021
    Publication date: September 7, 2023
    Inventors: GLEN HUGHES, RUTH E. MARCH, MARK ESSER, PATRICK MCTAMNEY II, YUEH-MING LOO, REENA M. VARKEY, QUN DU, JAMES STEINHARDT, SARAVANAN RAJAN
  • Publication number: 20230201346
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Application
    Filed: December 19, 2022
    Publication date: June 29, 2023
    Applicant: Boston Pharmaceuticals Inc.
    Inventors: Catherine ETTINGER, Jodi KARNELL, Melissa DAMSCHRODER, Partha CHOWDHURY, Xiaodong XIAO, Ping TSUI, Reena VARKEY, Stacey DRABIC, Laura CARTER, Ronald HERBST, Qun DU, Brian Michael NAIMAN
  • Publication number: 20230183358
    Abstract: The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The antibody molecules and conjugates find application in the treatment of cancer, for example.
    Type: Application
    Filed: November 9, 2022
    Publication date: June 15, 2023
    Inventors: Frank Irvine COMER, Yariv MAZOR, Srinath KASTURIRANGAN, Qun DU, Chunning YANG, Andrew Grier BUCHANAN
  • Patent number: 11578119
    Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: February 14, 2023
    Assignees: MedImmune LLC, Humabs BioMed SA
    Inventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
  • Patent number: 11529415
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: December 20, 2022
    Assignee: Boston Pharmaceuticals Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Publication number: 20220089699
    Abstract: The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (ClfA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 24, 2022
    Inventors: Christine TKACZYK, Bret SELLMAN, Qun DU, Melissa DAMSCHRODER, Taylor COHEN
  • Publication number: 20220041694
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of using such antibodies and antigen-binding fragments thereof for the prevention and treatment of Coronavirus Disease 2019 (COVID-19) in a subject.
    Type: Application
    Filed: August 9, 2021
    Publication date: February 10, 2022
    Inventors: Robert GASSER, Mark ESSER, Patrick MCTAMNEY, II, Yueh-Ming LOO, Reena M. VARKEY, Qun DU, James STEINHARDT, Saravanan RAJAN
  • Publication number: 20210363229
    Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.
    Type: Application
    Filed: June 7, 2021
    Publication date: November 25, 2021
    Inventors: Christine TKACZYK, Bret SELLMAN, Qun DU, Melissa DAMSCHRODER, Davide CORTI, Andrea MINOLA
  • Publication number: 20210355196
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and selecting the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2 infection in subject.
    Type: Application
    Filed: May 17, 2021
    Publication date: November 18, 2021
    Applicant: AstraZeneca UK Limited
    Inventors: Mark ESSER, James STEINHARDT, Patrick MCTAMNEY, II, Yueh-Ming LOO, Reena M. VARKEY, Qun DU, Saravanan RAJAN
  • Patent number: 11168133
    Abstract: The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (ClfA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 9, 2021
    Assignee: MedImmune, LLC
    Inventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Taylor Cohen
  • Patent number: 11059884
    Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: July 13, 2021
    Assignees: MedImmune, LLC, Humabs BioMed SA
    Inventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
  • Publication number: 20200164069
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Application
    Filed: February 5, 2020
    Publication date: May 28, 2020
    Applicant: Boston Pharmaceuticals Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Publication number: 20200109190
    Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 9, 2020
    Inventors: Christine TKACZYK, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
  • Publication number: 20200109189
    Abstract: The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (C1fA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 9, 2020
    Inventors: Christine TKACZYK, Bret SELLMAN, Qun DU, Melissa DAMSCHRODER, Taylor COHEN